Experience with experimental biological treatment and local gene therapy in Sjögren's syndrome: Implications for exocrine pathogenesis and treatment

Annals of the Rheumatic Diseases

Volumn 65, Issue 11, 2006, Pages 1406-1413

  Lodde, B M ^a,b   Baum, B J ^a   Tak, P P ^b   Illei, G ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CD20 ANTIBODY; CORTICOSTEROID; CYCLOSPORIN A; EPRATUZUMAB; ETANERCEPT; FAS ANTIGEN; FAS LIGAND; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN G; INFLIXIMAB; INTERLEUKIN 10; OKT 4; PREDNISONE; RITUXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASOACTIVE INTESTINAL POLYPEPTIDE;

APOPTOSIS; B LYMPHOCYTE; BIOLOGICAL MODEL; BIOLOGICAL THERAPY; CLINICAL TRIAL; DRUG HALF LIFE; ENZYME INHIBITION; EXOCRINE GLAND; EXPERIMENTAL THERAPY; GENE THERAPY; GENE TRANSFER; HUMAN; KERATOCONJUNCTIVITIS SICCA; LACRIMAL GLAND; MEDICAL LITERATURE; NONHUMAN; PALLIATIVE THERAPY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SALIVARY GLAND; SERUM SICKNESS; SJOEGREN SYNDROME; UNSPECIFIED SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRUS VECTOR; XEROSTOMIA;

ANIMALS; BIOLOGICAL RESPONSE MODIFIERS; DISEASE MODELS, ANIMAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; SJOGREN'S SYNDROME;

EID: 33750352359     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.052761     Document Type: Review

References (85)

1. Cha S, Peck AB, Humphreys-Beher MG. Progress in understanding autoimmune exocrinopathy using the non-obese diabetic mouse: an update. Crit Rev Oral Biol Med 2002;13:5-16.
2. Borchers AT, Naguwa SM, Keen CI, Gershwin ME. Immunopathogenesis of Sjogren's syndrome. Clin Rev Allergy Immunol 2003;25:89-104.
3. Moutsopoulous HM. Sjogren's syndrome: autoimmune epithelitis. Clin Immunol Immunopathol 1994;72:162-5.
4. Humphreys-Beher AAG, Peck AB. New concepts for the development of autoimmune exocrinopathy derived from studies with the NGO mouse model. Arch Oral Biol 1999;44(Suppl 1):S21-5.
5. Manganelli P, Fietta P. Apoptosis and Sjogren syndrome. Semin Arthritis Rheum 2003;33:49-65.
6. Fox RI, Stern M. Sjogren's syndrome: mechanisms of pathogenesis involve interaction of immune and neurosecretory systems. Scand J Rheumatol Suppl 2002:3-13.
7. Hocevar A, Tomsic M, Praprotnik S, Hojnik M, Kveder T, Rozman B. Parasympatnetic nervous system dysfunction in primary Sjogren's syndrome. Ann Rheum Dis 2003;62:702-4.
8. Pillemer SR, Smith J, Fox PC, Bowman SJ. Outcome measures for Sjogren's syndrome, April 10-11, 2003, Bethesda, Maryland, USA. J Rheumatol 2005;32:143-9.
9. Delaleu N, Jonsson M, Jonsson R. Disease mechanisms of Sjögren's syndrome. Drug Discov Today Dis Mech 2004;1:329-36.
10. van Woerkom JM, Kruize AA, Wenting-van Wijk MJ, Knol E, Bihari IC, Jacobs JW, et al. Salivary gland and peripheral blood T helper 1 and 2 cell activity in Sjogren's syndrome compared with non-Sjogren's sicca syndrome. Ann Rheum Dis 2005;64:1474-9.
11. Pertovaara M, Antonen J, Hurme M. Th2 cytokine genotypes are associated with a milder form of primary Sjogren's syndrome. Ann Rheum Dis 2006;65:666-70.
12. Mitsias DI, Tzioufas AG, Veiopoulou C, Zintzaras E, Tassios IK, Kogopoulou O, et al. The Th1/Th2 cytokine balance changes with the progress of the immunopathological lesion of Sjogren's syndrome. Clin Exp Immunol 2002;128:562-8.
13. Hjelmervik TO, Petersen K, Jonassen I, Jonsson R, Bolstad AI. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren's syndrome patients from healthy control subjects. Arthritis Rheum 2005;52:1534-44.
14. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmocytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006;103:2770-5.
15. Stott W, Hiepe F, Hummel M, Steinhauser G, Berek C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 1998;102:938-46.
16. Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003;62:168-71.
17. Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005;1050:34-9.
18. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 2005;62:421-8.
19. Kok MR, Baum BJ, Tak PP, Pillemer SR. Use of localised gene transfer to develop new treatment strategies for the salivary component of Sjogren's syndrome. Ann Rheum Dis 2003;62:1038-46.
20. Bolstad AI, Jonsson R. Gene therapeutics in Sjogren's syndrome. Expert Opin Biol Ther 2005;5:763-72.
21. Lai CM, Lai YK, Rakoczy PE. Adenovirus and adeno-associated virus vectors. DNA Cell Biol 2002;21:895-913.
22. Baum BJ, Wellner RB, Zheng C. Gene transfer to salivary glands. Int Rev Cytol 2002;213:93-146.
23. Fischer A, Abina SH, Thrasher A, von Kalle C, Cavazzana-Caivo M. IMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med 2004;350:2526-7.
24. Conlon TJ, Flotte TR. Recombinant adeno-associated virus vectors for gene therapy. Expert Opin Biol Ther 2004;4:1093-101.
25. van Błoklond SC, Versnel MA. Pathogenesis of Sjogren's syndrome: characteristics of different mouse models for autoimmune exocrinopathy. Clin Immunol 2002;103:111-24.
26. Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, et al. Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjogren's syndrome. Hum Gene Ther 2003;14:1605-18.
27. Thompson C, Jacobsen H, Pomeranz Krummel D, Nagai K, Cooke A. Non-depleting anti-CD4 antibody not only prevents onset but resolves sialadenitis in NOD mice. Autoimmunity 2004;37:549-54.
28. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun 2003;20:281-5.
29. Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Ritter T, Labree L, et al. Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis. Invest Ophthalmol Vis Sci 2004;45:1375-81.
30. Saito I, Haruta K, Shimuta M, Inoue H, Sakurai H, Yamada K, et al. Fas ligand-mediated exocrinopathy resembling Sjogren's syndrome in mice transgenic for IL-10. J Immunol 1999;162:2488-94.
31. Garcic-Carrasco M, Font J, Filella X, Cervera R, Ramos-Casals M, Siso A, et al. Circulating levels of Th1/Th2 cytokines in patients with primary Sjogren's syndrome: correlation with clinical and immunological features. Clin Exp Rheumatol 2001;19:411-15.
32. Anaya JM, Correa PA, Herrera M, Eskdale J, Gollagher G. Interleukin 10 (IL-10) influences autoimmune response in primary Sjogren's syndrome and is linked to 1L-10 gene polymorphism. J Rheumatol 2002;29:1874-6.
33. Ohyama Y, Nokamura S, Matsuzaki G, Shinohara M, Hiroki A, Fujimura T, et al. Cytokine messenger RNA expression in the labial salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 1996;39:1376-84.
34. Sun D, Emmert-Buck MR, Fox PC. Differential cytokine mRNA expression in human labial minor salivary glands in primary Sjogren's syndrome. Autoimmunity 1998;28:125-37.
35. Koski H, Janin A, Humphreys-Beher MG, Sorsa T, Malmstrom M, Konttinen YT. Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome. Clin Exp Rheumatol 2001;19:131-7.
36. Zhu Z, Stevenson D, Schechter JE, Mircheff AK, Crow RW, Atkinson R, et al. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea 2003;22:343-51.
37. Trousdale MD, Zhu Z, Stevenson D, Schechter JE, Ritter T, Mircheff AK. Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J Autoimmune Dis 2005;2:6.
38. Kok MR, Lodde BM, van Mello NM, Wang J, Goldsmith C, Chiorini JA, et al. Disease modifying effects of local tumor necrosis factor alpha receptor gene transfer in a murine model of Sjögren's syndrome [abstract]. Proceedings of the Annual Meeting American College of Rheumatology, San Antonio. San Antonio: ACR, 17-21 October 2004:1120.
39. Said SI. Vasoactive intestinal peptide. J Endocrinol Invest 1986;9:191-200.
40. Lodde RM, Mineshiba F, Wang J, Cotrim AP, Afione S, Tak PP, et al. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006;65:195-200.
41. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 1999;162:1707-16.
42. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide? FASEB J 2004;18:1325-34.
43. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000;18:621-63.
44. Fu D, Kobayashi M, Lin L. A p105-based inhibitor broadly represses NF-kappa B activities. J Biol Chem 2004;279:12819-26.
45. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001;107:7-11.
46. Arakaki R, Ishimaru N, Saito I, Kobayashi M, Yasui N, Sumida T, et al. Development of autoimmune exocrinopathy resembling Sjogren's syndrome in adoptively transferred mice with autoreactive CD4+ T cells. Arthritis Rheum 2003;48:3603-9.
47. Witte T, Matthias T, Oppermann M, Helmke K, Peter HH, Schmidt RE, et al. Prevalence of antibodies against alpha-fodrin in Sjogren's syndrome: comparison of 2 sets of classification criteria. J Rheumatol 2003;30:2157-9.
48. Ulbricht KU, Schmidt RE, Witte T. Antibodies against alpha-fodrin in Sjogren's syndrome. Autoimmun Rev 2003;2:109-13.
49. Yanagi K, Ishimaru N, Haneji N, Saegusa K, Saito I, Hayashi Y. Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjogren's syndrome. Eur J Immunol 1998;28:3336-45.
50. Hayashi Y, Ishimaru N, Arakaki R, Tsukumo S, Fukui H, Kishihara K, et al. Effective treatment of a mouse model of Sjogren's syndrome with eyedrop administration of anti-CD4 monoclonal antibody. Arthritis Rheum 2004;50:2903-10.
51. Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjogren's syndrome. Curr Allergy Asthma Rep 2005;5:327-32.
52. Tsubota K, Fujita H, Tadano K, Takeuchi T, Murakami T, Saito I, et al. Improvement of lacrimol function by topical application of CyA in murine models of Sjogren's syndrome. Invest Ophthalmol Vis Sci 2001;42:101-10.
53. Strong B, Farley W, Stern ME, Pflugfelder SC. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea 2005;24:80-5.
54. Kong L, Ogawa N, Nakabayashi T, Liu GT, D'Souza E, McGuff HS, et al. Fas and Fas ligand expression in the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 1997;40:87-97.
55. Kong L, Ogawa N, McGuff HS, Nakabayashi T, Sakata KM, Masago R, et al. Bcl-2 family expression in salivary glands from patients with primary Sjogren's syndrome: involvement of Box in salivary gland destruction. Clin Immunol Immunopathol 1998;88:133-41.
56. Fleck M, Zhang HG, Kern ER, Hsu HC, Muller-Ladner U, Mountz JD. Treatment of chronic sialadenitis in a murine model of Sjogren's syndrome by local fasL gene transfer. Arthritis Rheum 2001;44:964-73.
57. Fleck M, Kern ER, Zhou T, Lang B, Mountz JD. Murine cytomegalovirus induces a Sjogren's syndrome-like disease in C57Bl/6-lpr/lpr mice. Arthritis Rheum 1998;41:2175-84.
58. Wu AJ, Chen ZJ, Tsokos M, O'Connell BC, Ambudkar IS, Baum BJ. Interferon-gamma induced cell death in a cultured human salivary gland cell line. J Cell Physiol 1996;167:297-304.
59. Raz I, Eldor R, Naparstek Y. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol 2005;23:128-34.
60. Leiter EH, Serreze DV, Prochazka M. The genetics and epidemiology of diabetes in NOD mice. Immunol Today 1990;11:147-9.
61. Baxter AG, Koulmanda M, Mandel TE. High and low diabetes incidence nonobese diabetic (NOD) mice: origins and characterisation. Autoimmunity 1991;9:61-7.
62. Ohsugi T, Kurosawa T. Increased incidence of diabetes mellitus in specific pathogen-eliminated offspring produced by embryo transfer in NOD mice with low incidence of the disease. Lab Anim Sci 1994;44:386-8.
63. Lodde BM, Mineshiba F, Kok MR, Wang J, Zheng C, Schmidt M, et al. NOD mouse model for Sjögren's Syndrome: lack of longitudinal stability. Oral diseases. In press.
64. Steinfeld SD, Demols P, Salmon I, Kiss R, Appelboom T. Infliximab in patients with primary Sjogren's syndrome: a pilot study. Arthritis Rheum 2001;44:2371-5.
65. Steinfeld SD, Demols P, Appelboom T. Infliximab in primary Sjogren's syndrome: one-year followup. Arthritis Rheum 2002;46:3301-3.
66. Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). Arthritis Rheum 2004;50:1270-6.
67. Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 2004;50:2240-5.
68. Zandbelt MM, de Wilde P, van Damme P, Hoyng CB, van de Putte L, van den Hoogen F. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. J Rheumatol 2004;31:96-101.
69. Pillemer SR, Leakan RA, Sankar V, Manny J, Baum BJ, Smith J, et al. Prominent adverse effects of thalidomide in primary Sjogren's syndrome. Arthritis Rheum 2004;51:505-6.
70. Gutierrez-Rodriguez O. Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum 1984;27:1118-21.
71. Keesal N, Wasserman MJ, Bookman A, Lapp V, Weber DA, Keystone EC. Thalidomide in the treatment of refractory rheumatoid arthritis. J Rheumatol 1999;26:2344-7.
72. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003;49:585-93.
73. Bȧve U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML, et al. Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 2005;52:1185-95.
74. Smith JK, Siddiqui AA, Modica LA, Dykes R, Simmons C, Schmidt J, et al. Interferon-alpha upregulates gene expression of aquaporin-5 in human parotid glands. J Interferon Cytokine Res 1999;19:929-35.
75. Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology 2000;107:631-9.
76. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C. Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 2001;42:90-5.
77. Ramos-Casals M, Tzioufas AG, Font J. Primary Sjogren's syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64:347-54.
78. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 1978;89:888-92.
79. Pijpe J, van Imhoff GW, Spijkervet FK, Roodenburg JL, Wolbink GJ, Mansour K, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50.
80. Gottenberg JE, Guillevin L, Lambotte O, Combe B, Allanore Y, Cantagrel A, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20.
81. Steinfeld SD, Pradier O, Song I, Burmester GR, Wegener WA, Xu L, et al. Epratuzumab (anti-CD22) for the treatment of primary Sjögren's syndrome [abstract]. Proceedings of the Annual Meeting of the American College of Rheumatology, San Diego. San Diego: ACR, 13-17 November 2005:681.
82. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995;270:286-90.
83. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000;109:16-22.
84. Fox PC, Datiles M, Atkinson JC, Macynski AA, Scott J, Fletcher D, et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol 1993;11:149-56.
85. Izumi M, Eguchi K, Nakamura H, Takagi Y, Kawabe Y, Nakamura T. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome. Ann Rheum Dis 1998;57:464-9.